Linagliptin and Empagliflozin

Therapeutic indications

Linagliptin and Empagliflozin is indicated for:

Type 2 diabetes mellitus

Population group: only adults (18 years old or older)

The fixed dose combination of empagliflozin and linagliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus:

to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of empagliflozin/linagliptin do not provide adequate glycaemic control
when already being treated with the free combination of empagliflozin and linagliptin

For this indication, competent medicine agencies globally authorize below treatments (click for details):

10 mg empagliflozin / 5 mg linagliptin once daily that can be increased to 25 mg/5 mg once daily

Contraindications

Linagliptin and Empagliflozin is contraindicated in the following cases:

Pregnancy

Lactation

End stage renal diseas, patients on dialysis

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

1,5-anhydroglucitol assay

at least one of

1,5-ANHYDRO-D-GLUCITOL
Glucose measurement

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.